Cerebras IPO Soars 89% on First Day; AI Chipmaker Raises $5.55B in Largest Tech IPO of Year
Cerebras Systems, an AI chipmaker, raised $5.55 billion in an upsized IPO on May 14, with shares indicated to surge 89% above the offering price on day one. The breakthrough valuation reflects sustained conviction in AI infrastructure capex and validates a crowded semiconductor ecosystem beyond NVIDIA.
RKey facts
- Cerebras IPOInitial Public Offering - a company's first public sale of stock. raised $5.55 billion, year's largest technology IPO
- Shares indicated to surge 89% above offering price on first trading day
- CEO Andrew Feldman's personal stake valued at ~$3.2 billion
- IPOInitial Public Offering - a company's first public sale of stock. validates broader AI infrastructure demand beyond NVIDIA
What's happening
Cerebras Systems Inc., a specialist chipmaker focused on training large language models, completed the year's largest technology IPOInitial Public Offering - a company's first public sale of stock., raising $5.55 billion at an upsized offering price. Shares opened up roughly 89% on the first day, a validation of the market's appetite for AI infrastructure beneficiaries beyond NVIDIA. CEO Andrew Feldman, a serial entrepreneur who previously took three companies to exit and one to IPO, is now controlling an $3.2 billion personal fortune on paper.
The Cerebras pop underscores a broadening narrative: the AI buildout is so vast that a single megacap (NVDA) cannot absorb all the demand. Equipment makers, specialized chip designers, and infrastructure software companies are all seeing investor enthusiasm. Broadcom (AVGO) and other analog/RF players have benefited from this dispersion. The Cerebras success also validates venture and growth-stage investors who backed AI infrastructure plays early, opening a new exit avenue for what had been a crowded funding landscape.
The timing is critical: with NVIDIA approaching $6 trillion in valuation and facing valuation concerns, Cerebras offers a lower-priced entry point for investors who believe the AI capex thesis but worry about NVDA's stretched multiples. Institutional buyers, particularly asset managers benchmarked to the Nasdaq, are diversifying AI exposure across the supply chain. For semiconductor equipment makers like ASML and Applied Materials, the Cerebras IPOInitial Public Offering - a company's first public sale of stock. validates sustained demand for their products over a multi-year cycle.
Skeptics argue that IPOInitial Public Offering - a company's first public sale of stock. pops are often followed by postlisting underperformance, and that Cerebras faces stiff competition from established players like NVIDIA, AMD, and custom silicon efforts from hyperscalers themselves (Google TPU, Amazon Trainium). The company is also relatively unproven in revenue generation compared to NVIDIA. However, the sheer magnitude of the IPO proceeds and the enthusiasm suggest institutional conviction that the AI capex cycle is real, broad, and worth paying premium valuations for.
What to watch next
- PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Matrix Service Company - MTRX
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Matrix Service Company ("Matrix" or the "Company") (NASDAQ: MTRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
23m ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BayCom Corp - BCML
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BayCom Corp ("BayCom" or the "Company") (NASDAQ: BCML). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation...
1h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation...
1h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forward Air Corporation - FWRD
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forward Air Corporation ("Forward Air" or the "Company") (NASDAQ: FWRD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
1h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
1h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veritone, Inc. - VERI
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Veritone, Inc. ("Veritone" or the "Company") (NASDAQ: VERI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation...
1h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
1h ago - PR Newswire FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Angi Inc. - ANGI
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Angi Inc. ("Angi" or the "Company") (NASDAQ: ANGI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns...
1h ago
Related coverage
- US Approves NVIDIA H200 Chip Sales to 10 Chinese CompaniesTech & AI··0 mentions
- Cisco Signals AI Networking Buildout Expanding Into Switches, Optics; CSCO Up on Infrastructure BreadthTech & AI··0 mentions
- NVDA Hits Record $6 Trillion Valuation After 20% Rally; Peak Debate IntensifiesTech & AI··0 mentions
- Cerebras IPO Surges 89% Above Listing; AI Chipmaker Valuation Breakout Signals Sector MomentumTech & AI··0 mentions
More about $NVDA
- Top 10 US Stocks Now Drive Record Share of SPY Gains; Breadth Concerns Mount·Equities US
- Cerebras IPO Raises $5.55B, Shares Indicated Up 89% on AI Chip Appetite·Tech & AI
- US Approves $NVDA H200 Chip Sales to China; Beijing Trip Sparks Demand Optimism·Tech & AI
- S&P 500, Nasdaq Hit Records on AI Rally; Only 1 in 4 Active Managers Beating Market·Equities US
- Cerebras IPO Surges 89% on Listing; AI Chipmaker Raises $5.55 Billion·Tech & AI
Live coverage of the AI semiconductor cycle — NVDA, AVGO, AMD, ASML, memory demand, capex run rates and overbought signals.